US 12,213,975 B2
PDE9 inhibitors for treating sickle cell disease
Edward George Calamai, Boston, MA (US); Deborah Lynn Leithead Dobbins, Boston, MA (US); Michael Paul Dehart, Boston, MA (US); James McArthur, Boston, MA (US); and Shi Yin Foo, Boston, MA (US)
Assigned to Cardurion Pharmaceuticals, Inc., Burlington, MA (US)
Filed by Cardurion Pharmaceuticals, Inc., Burlington, MA (US)
Filed on Feb. 26, 2021, as Appl. No. 17/186,442.
Application 17/186,442 is a continuation of application No. PCT/US2019/048898, filed on Aug. 29, 2019.
Claims priority of provisional application 62/725,725, filed on Aug. 31, 2018.
Prior Publication US 2021/0177845 A1, Jun. 17, 2021
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/284 (2013.01); A61P 7/06 (2018.01)] 7 Claims
 
1. An oral tablet composition, comprising:
50 mg 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1),
about 20%, about 30%, or about 40% by weight microcrystalline cellulose (MCC),
about 1% by weight colloidal silicon dioxide, and
about 0.8% by weight magnesium stearate.